Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-jRCT2031210404
- Lead Sponsor
- Contact for Clinical Trial Information
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer.
Exclusion Criteria
Participants who has a history of hypersensitivity to any component of brigatinib.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of Participants with Adverse Events Related to Interstitial Lung Disease<br>Time Frame; Up to 1 year<br>An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product. They are not limited to the events with clear causal relationship with treatment with concerned drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
- Secondary Outcome Measures
Name Time Method